AUTHOR=Zhang Yu , Zhang Hao , Wang Hanqing , Zeng Jingtong , Zhang Bo , Zhou Ning , Zu Lingling , Song Zuoqing , Wang Changli , Xu Song 

TITLE=Use of savolitinib as neoadjuvant therapy for non–small cell lung cancer patient with MET exon 14 skipping alterations: A case report

JOURNAL=Frontiers in Oncology

VOLUME=Volume 12 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.968030

DOI=10.3389/fonc.2022.968030

ISSN=2234-943X

ABSTRACT=Savolitinib is a tyrosine kinase inhibitor being developed for the treatment of metastatic non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition factor (MET) exon 14-skipping alterations. However, the role of savolitinib in neoadjuvant therapy for lung cancer remains unclear. Herein, we present a case of a 65-year-old woman diagnosed with stage IIIA (cT2bN2M0, 8th TNM stage) upper right lung adenocarcinoma harboring MET exon 14-skipping alterations. After four weeks of therapy, a partial response was achieved with neoadjuvant savolitinib, and significant shrinkage in tumor and lymph nodes was observed. We also measured the immune microenvironment of the primary tumor pre- and post-treatment with savolitinib.